This and previously mentioned studies predict highest effects of an IL‐4 signaling blockade on tumor‐initiating/CSC‐like cells leading to the conclusion that an anti‐IL‐4/STAT6 therapy may have considerable potential in combination with a therapy that is directed against the bulk of tumor cells. Here, STAT6 is linked to neoplasm.